KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) EPS (Weighted Average and Diluted) (2019 - 2025)

GoodRx Holdings' EPS (Weighted Average and Diluted) history spans 7 years, with the latest figure at $0.02 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) changed 0.0% year-over-year to $0.02; the TTM value through Dec 2025 reached $0.09, up 80.0%, while the annual FY2025 figure was $0.09, 125.0% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.02 at GoodRx Holdings, up from $0.0 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.14 in Q2 2023 and bottomed at -$0.1 in Q3 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is $0.0 (2025), against an average of -$0.0.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 4177.66% in 2023 against a maximum downside of 500.0% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.09 in 2021, then surged by 88.89% to -$0.01 in 2022, then crashed by 500.0% to -$0.06 in 2023, then surged by 133.33% to $0.02 in 2024, then fell by 0.0% to $0.02 in 2025.
  • Per Business Quant, the three most recent readings for GDRX's EPS (Weighted Average and Diluted) are $0.02 (Q4 2025), $0.0 (Q3 2025), and $0.04 (Q2 2025).